EXCEED THE SPACE PROVIDED. Chemokines are low molecular-weight cytokines with a wide range of biological activities. Although initially characterized as leukocyte chemoattractants, chemokines are now recognized to influence many physiologic processes including organogenesis, tumor growth and metastasis, lymphocyte trafficking and wound healing. The two major processes governed by chemokines are cell migration and cell proliferation; recent data in liver, however, suggest that chemokines protect against acute forms of toxic injury. The cytoprotective role of chemokines has been putatively assigned to one subfamily of peptides designated CXC. The beneficial properties of CXC chemokines have not been fully characterized. Documenting the salutary effects of CXC chemokines toward liver cells and elucidating their mechanism of action are the primary objectives of this proposal. Our fundamental hypothesis is that CXC chemokines inhibit hepatocyte apoptosis. Experiments are designed to characterize this anti-apoptotic effect in vivo and in cell culture, using galactosamine and endotoxin as a model hepatotoxin. Particularly important are studies involving bone marrow chimeras between CXCR2 +/+ and CXCR2 -/- mice, which are necessary to distinguish the cytoprotective effects of chemokines toward hepatocytes in vivo from their activity as leukocyte chemoattractants. Studies in isolated hepatocytes are intended to document CXC chemokine receptor expression in hepatocytes, using real-time PCR, FACS, and monitoring of chemokine-induced signaling. Additional studies will focus on the mechanism by which chemokines prevent apoptosis. Findings to date point to activation of PI-3 kinase as a critical step in this process. Experiments will examine relevant anti- apoptotic consequences of PI-3 kinase activation, specifically phosphorylation of Akt, activation of NF-kB, and up-regulation of Bcl-xL. In sum, the proposed studies will provide a comprehensive view of the activity of CXC chemokines in liver. Uncovering a potential benefit of CXC chemokines is of critical importance, because neutralization of these compounds is being considered as a clinical approach to inflammatory diseases. If chemokines have significant cytoprotective effects, then anti-chemokine therapy may be complicated by unwanted side effects. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK061510-03
Application #
6840548
Study Section
Alcohol and Toxicology Subcommittee 4 (ALTX)
Program Officer
Doo, Edward
Project Start
2003-02-01
Project End
2007-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$320,423
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Niemann, Claus U; Xu, Fengyun; Choi, Soojinna et al. (2010) Short passive cooling protects rats during hepatectomy by inducing heat shock proteins and limiting the induction of pro-inflammatory cytokines. J Surg Res 158:43-52
Maher, Jacquelyn J (2009) DAMPs ramp up drug toxicity. J Clin Invest 119:246-9
Maher, Jacquelyn J; Leon, Pablo; Ryan, James C (2008) Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 48:670-8
Liao, Mingxiang; Pabarcus, Michael K; Wang, YongQiang et al. (2007) Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor. J Pharmacol Exp Ther 323:979-89
Rizki, Gizem; Arnaboldi, Lorenzo; Gabrielli, Bianca et al. (2006) Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 47:2280-90
Hanson, Jennifer C; Bostick, Michele K; Campe, Carson B et al. (2006) Transgenic overexpression of interleukin-8 in mouse liver protects against galactosamine/endotoxin toxicity. J Hepatol 44:359-67
Kodali, Pratima; Wu, Ping; Lahiji, Parshawn A et al. (2006) ANIT toxicity toward mouse hepatocytes in vivo is mediated primarily by neutrophils via CD18. Am J Physiol Gastrointest Liver Physiol 291:G355-63
Han, Xing-Mei; Lee, Gene; Hefner, Colleen et al. (2005) Heme-reversible impairment of CYP2B1/2 induction in heme-depleted rat hepatocytes in primary culture: translational control by a hepatic alpha-subunit of the eukaryotic initiation factor kinase? J Pharmacol Exp Ther 314:128-38
Xu, Junquan; Lee, Gene; Wang, Haimei et al. (2004) Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol 287:G734-41